HALO - Halozyme's early 2023 results indicate a mixed performance
2024-01-17 08:53:24 ET
More on Halozyme Therapeutics
- Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway
- Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript
- Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Halozyme gains as U.S. and EU clear Enhanze-based products
- JNJ multiple myeloma therapy outperforms standard of care by 58%
For further details see:
Halozyme’s early 2023 results indicate a mixed performance